Objective: To investigate the effects of small-interfering RNA (siRNA)-mediated silencing of SET binding factor 2 (SBF2) on pancreatic cancer cells and its underlying molecular mechanisms. Methods: Five siRNAs, namely, siRNA-1, siRNA-2, siRNA-3, siRNA-4, and siRNA-5, were designed to silence SBF2 in pancreatic cancer PANC-1 cells. The relative expression levels of SBF2 after siRNA-mediated SBF2 silencing were detected by real-time polymerase chain reaction (RT-PCR). The inhibition and apoptosis of cells were detected by methyl thiazolyl tetrazolium and flow cytometry, respectively. The protein concentrations of SBF2, SMAD-2, phosphorylated-SMAD-2 (p-SMAD-2), SMAD-3, p-SMAD-3, and SMAD-7 were also measured via Western blot. Results: The relative expression levels of SBF2 in the siRNA-mediated SBF2-silenced groups decreased significantly (P < .05), and the proliferation of PANC-1 cells was significantly inhibited (P < .01) after SBF2 silencing using the 5 siRNAs. The relative expression level of SBF2 was the lowest (0.52 + 0.05) and the cell inhibition rate was the highest (36.7 + 4.0%) in the SBF2-silenced PANC-1 cells using siRNA-3 compared to the 5 siRNA-mediated SBF2silenced groups. The cell apoptosis rate in the siRNA-3 transfection group was significantly higher than that in the control group (P < .05). The concentrations of p-SMAD-2 and p-SMAD-3 were reduced, while the concentrations of SMAD-2, SMAD-3, and SMAD-7 were increased in the siRNA-3-mediated SBF2-silenced PANC-1 cells. Conclusion: SiRNA-mediated SBF2 silencing could significantly inhibit the proliferation and promote the apoptosis of pancreatic cancer cells possibly via attenuation of transforming growth factor b/SMAD signaling pathway. And SBF2 silencing can be a potential approach for treatment of pancreatic cancer.
Introduction
Pancreatic cancers have become the fourth leading cause of cancer-related deaths in the Western world. 1 Despite many surgical and chemotherapeutic approaches have been used for pancreatic cancer therapy, less than 5% patients with pancreatic cancer survive for 5 years. 1 Thus, novel approaches were required to improve the efficacy of pancreatic cancer treatment. To date, adjuvant therapy, 2 tumor-selective targets, 3 and nanomedicine 4, 5 have been applied for the treatment of pancreatic cancer. However, the mortality rate of pancreatic cancer has not obviously declined. In order to provide novel effective approaches for pancreatic cancer treatment, molecular mechanisms of pancreatic cancers need to be further elucidated.
Up to now, our knowledge on the pathogenesis of pancreatic cancer at the genetic level is still very limited. Mutations in the oncogene KRAS (Kirsten rat sarcoma viral oncogene homolog), loss of tumor suppressor genes like SMAD-4 (SMAD family member 4) and TP53 (Tumor Protein 53), activation of downstream transcription factors (such as signal transducer and activator of transcription type 3 and nuclear factor kB), and deregulation of CXCR2 (C-X-C Chemokine Receptor Type 2) ligands like CXCL1 (C-X-C Motif Chemokine 1) and CXCL5 (C-X-C Motif Chemokine 5), and cytokines (interleukin [IL] 1 [IL-1], IL-6, IL-8, and tumor necrosis factor a) are believed to be associated with the initiation and progression of pancreatic cancer. PALB2 (partner and localizer of BRCA2) gene has also been identified to be a susceptibility gene of pancreatic cancer. 6 Wu et al have reported that genetic variation in the SET binding factor 2 (SBF2) locus is significantly related to the survival rate of patients with pancreatic adenocarcinoma in a 2-stage genome-wide association study, suggesting a vital role of this gene in pancreatic cancer. 7 However, the molecular mechanisms underlying the role of SBF2 in pancreatic cancer have never been reported so far. The SBF2 encodes a myotubularin-related protein (MTMR) 13 (MTMR13). The myotubularin family is a large eukaryotic group within the tyrosine/dual-specificity phosphatase (PTP/ DSP) super family, containing 14 genes in humans. 8 Myotubularin-related protein 4 (MTMR4) is another myotubularin family member, which has been previously reported to attenuate both the transforming growth factor b (TGF-b) signaling and bone morphogenetic protein/Drosophila ortholog, decapentaplegic signaling by dephosphorylation of SMAD proteins by Yu et al. 9, 10 Although TGF-b is implicated in cancers for long, 11, 12 its role remains complicated, which is supposed to suppress early tumorigenesis and later enhance tumor progression. [13] [14] [15] The TGF-b-signaling pathway involves 2 transmembrane serine/threonine kinases, namely, TbRII and TbRI. TbRII, a constitutively active kinase, binds TGF-b to initiate its heterodimerization with TbRI. TbRI then becomes phosphorylated and activates a signaling cascade through a family of intracellular signaling mediators known as SMADs. Phosphorylation of receptor-regulated SMADs (R-SMADs) leads to the formation of a trimeric complex with a common mediator SMAD (SMAD-4), which is then translocated into the nucleus, where the nuclear SMAD oligomers bind to DNA and regulate the expression of target genes via association with transcription factors. 16 Whether the role of SBF2 in pancreatic cancer is related to the TGF-b signaling has not been known yet.
In this study, we designed 5 small-interfering RNAs (siR-NAs) to restrain expression of SBF2. After silencing the SBF2 gene using siRNAs in pancreatic cancer PANC-1 cells, the changes in cell proliferation and apoptosis were detected. Furthermore, the concentrations of SBF2, SMAD-2, phosphorylated (p) SMAD-2 (p-SMAD-2), SMAD-3, p-SMAD-3, and SMAD-7 were also measured by Western blot analysis. Our study aimed to investigate the role of SBF2 in pancreatic cancer and to understand the molecular mechanisms underlying the effects of siRNA-mediated silencing of SBF2.
Materials and Methods

Cell culture
Pancreatic cancer cell line PANC-1 was purchased from Shanghai Cell Repository of Chinese Academy of Sciences. The cells were cultured in Gibco PRMI1640 culture medium (Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% HyClone fetal bovine serum (Thermo Fisher Scientific, Inc., Waltham, MA, USA) in a humidified air incubator (Sanyo, Japan) with 5% CO 2 at 37 C. Cells were passaged at 70% to 80% confluence.
Design of siRNA Primers
The specific siRNA of SBF2 gene was obtained from a siRNA primer design site http://sidirect2.rnai.jp. According to messenger RNA (mRNA) sequence (NM_030962.3) of SBF2 gene in Genebank database, 5 SBF2 siRNAs were designed and the sequences were shown in Table 1 . In addition, the negative control siRNA (siRNA-NC) with random sequences that did not target any gene was also designed. And all the siRNAs were synthesized by Shanghai GenePharma Co, Ltd (Shanghai, China).
Silencing of SBF2 Using siRNAs
The pancreatic cancer PANC-1 cells in the logarithmic phase were seeded into 6-well plates at the density of 2 Â 10 5 cells/mL 24 hours prior to transfection and allowed to adhere overnight. For each well, 50 mL of OPTI MEM medium (Gibco) containing 200 pmol SBF2-specific siRNA was added to 50 mL OPTI MEM medium containing Lipofectamine 2000 (Invitrogen, Carlsbad, California). Then, 100 mL of siRNA solution and transfection reagent were mixed gently and incubated for 5 minutes at room temperature according to the manufacturer's instruction. Then, the mixture was carefully dripped into the cells in 2 mL RPMI1640 medium without serum or antibiotic. The PANC-1 cells were treated with 5 siRNAs targeting SBF2, respectively, as well as the siRNA-NC. Meanwhile, a blank Table 1 . The Sequences of the 5 siRNA targeting SBF2 Gene and the Negative Control siRNA (siRNA-NC) With Random Sequences.
siRNA
Forward Primer
control group was also designed. After 4 hours, the RPMI1640 culture medium was replaced with medium supplemented with serum. Cells cultured for 4 hours were collected for determination of cell proliferation. Meanwhile, cells were also collected for real-time polymerase chain reaction (RT-PCR), apoptosis assay, and Western blot analysis after culturing for 48 hours.
Detection of SBF2 mRNA Expression in PANC-1 Cells
Total cellular RNA was extracted from PANC-1 cells using Trizol reagent (Invitrogen) and was reversely transcribed to complementary DNA using reverse transcription kit (Invitrogen) according to the manufacturer's instruction. The RT-PCR primers for SBF2 were designed through the online primer design website http://www.idtdna.com, and primers of b-actin were obtained from reference ( Table 2 ). 17 The RT-PCR amplification and measurement of relative amount of gene were performed with SYBR Green I (Thermo Fisher Scientific, Inc., Waltham, MA, USA). The PCR cycling conditions included 1 initial denaturation cycle at 95 C for 3 minutes, subsequent 40 cycles of amplification for 30 seconds at 95 C, 30 seconds at 60 C, and a final extension cycle of 30 seconds at 72 C. The actual amount of PCR product was measured by the intensity of fluorescence at each cycle. The standard curves were established by standard substances and b-actin was used as reference gene. The experiments were repeated 3 times and all the samples were performed in triplicate. The RT-PCR data were processed by the software of CFX-96 real-time PCR instrument (Bio-Rad, Hercules, USA).
Detection of Cell Proliferation
The cells were inoculated in 96-well plate at 2 Â 10 3 cells/well and incubated for 48 hours. Totally, 50 mL (1 mg/mL) of methyl thiazolyl tetrazolium (MTT) solution was added into each well for 2 hours. Then, the supernatant was removed and 150 mL of dimethyl sulfoxide was added into each well to solubilize the formazan crystals. The absorbance at 570 nm was detected by a microplate reader, and all determinations were carried out in triplicate. The inhibition ratio (IR) was calculated using the following formula: IR (%) ¼ (1 À A/ A') Â 100%, where A refers to the absorbance of transfected group and A' refers to the absorbance of control group.
Detection of Cell Apoptosis
The cells were collected by centrifugation at 1000 rpm for 5 minutes and washed twice using phosphate-buffered solution (PBS). Cells were resuspended in PBS and the concentration of cells was adjusted to 1 Â 10 6 cells/mL. Then, 100 mL of cells were mixed with 100 mL of Guava nexin (Milipore, Darmstadt, Germany) and incubated for 20 minutes at room temperature out of direct sunlight. The apoptosis of cells was detected by Guava flow cytometer (Milipore, Darmstadt, Germany).
Western Blot Analysis
The cells were washed 3 times with PBS, and then total proteins were extracted using cell lysis buffer in the ice bath for 30 minutes. After centrifugation at 12 000 rpm for 10 minutes at 4 C, the supernatant was collected and protein concentration was detected by Pierce BCA Protein Assay Kit (Thermo Fisher Scientific, Inc., Waltham, MA, USA) according to the manufacturer's instruction. Totally, 20 mL of protein was separated from each sample through sodium dodecyl sulfate polyacrylamide gel electrophoresis and transferred onto polyvinylidene difluoride membrane. After blocking with 5% skim milk powder (Wyeth, Vevey, Switzerland) for 2 hours, the membrane was incubated over night at 4 C with SBF2 primary antibodies (Abcam, Cambridge, Massachusetts; SMAD-2, p-SMAD-2 , SMAD-3, p-SMAD-3, and SMAD-7), followed by incubation with horseradish peroxidase-conjugated goat anti-rabbit immunoglobulin G secondary antibodies (Abcam) labeled with for 1 hour at room temperature. The immunoreactivity was measured by enhanced chemiluminescence reagent (Pierce) and exposed to X-ray films with b-actin as control. Each experiment was repeated 3 separate times.
Statistical Analysis
Statistical analysis was performed by SPSS 13.0 software (SPSS Inc, Chicago, Illinois). The measurement data were expressed as mean + square deviation and analyzed by t test. The difference is considered to be statistically significant at P <.05.
Results
Effects of the 5 siRNAs on SBF2 Gene Silencing
Total cellular RNA was extracted from PANC-1 cells in each group and RT-PCR was conducted. Compared with the control group, the relative expression levels of SBF2 gene in the 5 groups were all significantly decreased (Figure 1 ; P < 0.05), and the differences between siRNA-1, siRNA-2, or siRNA-3 group and the control were extremely significant (P < .01). And Table 2 . RT-PCR Primer Sequences for SBF2 Gene and b-Actin.
Genes Forward Primer
Reverse Primer
Abbreviation: RT-PCR, real-time polymerase chain reaction.
the relative expression level of SBF2 in the siRNA-3 interference group was the lowest (0.52 + 0.05).
Effect of SFB2 Silencing on the Proliferation of PANC-1 Cells
The inhibition of cells was detected by MTT assay. Compared with the siRNA-NC group, the growth of PANC-1 cells was significantly inhibited by SBF2 interference (Figure 2 ; P < .01).
In the siRNA-3-mediated SBF2-silenced PANC-1 cells, the inhibition of cell proliferation was the most obvious, with the inhibition rate of 36.7% + 4.0%.
Effects of SFB2 Silencing on the Apoptosis of PANC-1 Cells
Changes in the apoptosis of PANC-1 cells were detected by Guava flow cytometer in the siRNA-3-mediated, SFB2silenced PANC-1 cells and the control group. The cell apoptosis rate was significantly higher in the siRNA-3-mediated SFB2-silenced PANC-1 cells than that in the control group (29% vs 4%, P < .05; Figure 3 ).
Effect of SFB2 Silencing on Expression of SMAD in PANC-1 Cells
Western blotting was done to detect the concentrations of SMAD-2, SMAD-3, SMAD-7, p-SMAD-2, and p-SMAD-3 in the siRNA-3-mediated, SFB2-silenced PANC-1 cells and the control group. Compared with the control group, the concentrations of p-SMAD-2 and p-SMAD-3 were reduced, while the concentrations of SMAD-2, SMAD-3, and SMAD-7 were increased in the siRNA-3-mediated SFB2silenced group (Figure 4 ).
Discussion
It has been reported that gene SBF2 is correlated with the survival rate of patients with pancreatic adenocarcinoma. 7 However, no experimental proofs have been seen so far. To investigate its role in pancreatic cancer experimentally, the SBF2 gene in the pancreatic cancer PANC-1 cells was interfered by 5 siRNAs in the present study. And it was found that siRNA-mediated SBF2 silencing, especially siRNA-3mediated SBF2 silencing, could significantly inhibit the proliferation of pancreatic cancer cells and promote the apoptosis of pancreatic cancer cells, which also implies that SBF2 may have a positive role in the progression of pancreatic cancer.
To further investigate the possible molecular mechanism underlying the effect of siRNA-mediated SBF2 silencing on PANC-1 cells, the concentrations of p-SMAD-2, p-SMAD-3, SMAD-2, SMAD-3, and SMAD-7 proteins in the siRNAmediated SBF2-silenced cells were measured in the present study. Here, the concentrations of p-SMAD-2 and p-SMAD-3 were reduced in the siRNA3-mediated SBF2-silenced PANC-1 cells according to Western blot, while the concentrations of SMAD-2, SMAD-3, and SMAD-7 were increased, indicating that SBF2 silencing reduces the phosphorylation of SMAD proteins SMAD-2 and SMAD-3 while increases the expression of inhibitory SMAD, SMAD-7. Generally in TGF-b signaling pathway, after phosphorylation by TGF-b receptors, the activated R-SMADs (primarily SMAD-2 and SMAD-3) associate with the comediator SMAD, SMAD-4, and the heteromeric complex then translocates into the nucleus, where SMAD complexes activate specific genes through cooperative interactions with other DNAbinding and coactivator (or corepressor) proteins. 18 Both the upregulated expression of SMAD-7 and the decreased expression of p-SMAD-2 and p-SMAD-3 observed here may contribute to the inhibition of the TGF-b signaling pathway. It is thus supposed that the inhibition of proliferation and promotion of apoptosis of pancreatic cancer cells after SBF2-silencing are presumably attributed to the attenuation of the TGF-b signaling pathway due to reduced activated R-SMADs and increased inhibitory SMAD-7. And the PANC-1 cells is probably derived from a late-stage patient, as TGF-b signaling pathway is now acknowledged to promote progression of tumor at later stages. 12, 14 A previous study has demonstrated that MTMR4 attenuates the TGF-b signaling by dephosphorylating the activated R-SMADs in cytoplasm. 10 However, our finding has revealed that SBF2 may be involved in the phosphorylation of SMAD-2 and SMAD-3, as the expression of the 2 R-SMADs are downregulated after SBF2 silencing. Generally, the myotubularin family members are known as phosphatases that share 4 common domains: GRAM (glucosyltransferase, Rab-like GTPase activators, and myotubularins), RID (Rac-induced recruitment domain), PTP/ DSP (dual-specificity phosphatase) active site homology, and SID (SET-interacting domain). 8 Notably, other domains that may be related to special functions are also found in individual MTMRs. For example, a differentially expressed in neoplastic versus normal cells domain has been found in the MTMR5/ R13, which is usually found in some regulators of GTPases (eg, Rab3GEF involved in exocytosis), indicating the 2 MTMR members (MTMR5/R13) may have a GTPase effector activity. 19 Thus, this implies that MTMR13 may also be responsible for the phosphorylation of SMAD-2 and SMAD-3 in progression of pancreatic cancer. Additionally, as an inhibitory SMAD, SMAD-7 can inhibit the interaction of R-SMADs with SMAD-4 or receptors, thereby blocking the phosphorylation of R-SMADs, 20 which may also have a role in the reduction of R-SMADs observed in the present study. Thus, the mechanisms underlying how SBF2 affects the levels of R-SMADs and SMAD-7 need to be further investigated.
Conclusion
Thus, it can be concluded that SBF2, encoding another myotubularin member MTMR13, may promote the progression of pancreatic cancer via the TGF-b signaling by raising the activated R-SMADs and decreasing inhibitory SMAD-7, and thus SBF2-silencing by siRNA may inhibit the proliferation of pancreatic cancer cells and promote the apoptosis of pancreatic cancer cells by TGF-b signaling. Thus, silencing SBF2 using siRNA may be a promising approach for pancreatic cancer therapy.
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